Nova Biomedical to Host Webinar on COVID-19 Bedside Glucose Management

Risk of Ascorbic Acid and Hematocrit Interference That Can Elevate Glucose Meter Results
WALTHAM, Mass. - April 17, 2020 - PRLog -- Nova Biomedical to host "COVID-19 Bedside Glucose Management: Risk of Ascorbic Acid and Hematocrit Interference," a webinar led by Charbel Abou-Diwan, PhD, Director of Medical and Scientific Affairs, to help inform and support healthcare workers treating COVID-19 patients.

Interest in the antioxidant properties of ascorbic acid use in critically ill patients is growing especially during the in the COVID-19 pandemic. As clinicians search for effective treatments for COVID-19, sepsis, and other critical illness, high dose ascorbic acid is widely considered. For these critically ill patients, severe anemia is also a common occurrence Unfortunately, most used hospital glucose meters have a substantial interference from ascorbic acid and anemia that radically elevates glucose meter results, leading to potential adverse events. This webinar examines the risk of inaccurate glucose meter results due to ascorbic acid and hematocrit interference and how hospitals can protect their patients against this threat.

The webinar will be delivered on three dates: Thursday, April 30th at 2:00 PM EST, Thursday, May 28th at 1:00 PM EST, and Thursday, June 18th at 4:00 PM EST. Attendees can earn educational credits for attending and can register online at

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova's biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova's biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests with over 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan.

Richard Rollins
Source: » Follow
Email:*** Email Verified
Location:Waltham - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Nova Biomedical News
Most Viewed
Daily News

Like PRLog?
Click to Share